BACKGROUND: Asthma is a major public health problem that affects millions of children worldwide, and exacerbations account for most of its morbidity and costs. Primary-care providers lack efficient tools to identify children at high risk for exacerbations. We aimed to construct a clinical score to help providers to identify such children. METHODS: Our main outcome was severe asthma exacerbation, which was defined as any hospitalization, urgent visit, or systemic steroid course for asthma in the previous year, in children. A clinical score, consisting of a checklist questionnaire made up of 17 yes-no questions regarding asthma symptoms, use of medications and health-care services, and history, was built and validated in a cross-sectional study of Costa Rican children with asthma. It was then evaluated using data from the Childhood Asthma Management Program (CAMP), a longitudinal trial cohort of North American children. RESULTS: Compared with children at average risk for an exacerbation in the Costa Rican validation set, the odds of an exacerbation among children in the low-risk (OR, 0.2; 95% CI, 0.1-0.4) and high-risk (OR, 5.4; 95% CI, 1.5-19.2) score categories were significantly reduced and increased, respectively. In CAMP, the hazard ratios for an exacerbation after 1-year follow-up in the low-risk and high-risk groups were 0.6 (95% CI, 0.5-0.7) and 1.9 (95% CI, 1.4-2.4), respectively, with similar results at 2 years. CONCLUSIONS: The proposed Asthma Exacerbation Clinical Score is simple to use and effective at identifying children at high and low risk for asthma exacerbations. The tool can easily be used in primary-care settings.
BACKGROUND:Asthma is a major public health problem that affects millions of children worldwide, and exacerbations account for most of its morbidity and costs. Primary-care providers lack efficient tools to identify children at high risk for exacerbations. We aimed to construct a clinical score to help providers to identify such children. METHODS: Our main outcome was severe asthma exacerbation, which was defined as any hospitalization, urgent visit, or systemic steroid course for asthma in the previous year, in children. A clinical score, consisting of a checklist questionnaire made up of 17 yes-no questions regarding asthma symptoms, use of medications and health-care services, and history, was built and validated in a cross-sectional study of Costa Rican children with asthma. It was then evaluated using data from the Childhood Asthma Management Program (CAMP), a longitudinal trial cohort of North American children. RESULTS: Compared with children at average risk for an exacerbation in the Costa Rican validation set, the odds of an exacerbation among children in the low-risk (OR, 0.2; 95% CI, 0.1-0.4) and high-risk (OR, 5.4; 95% CI, 1.5-19.2) score categories were significantly reduced and increased, respectively. In CAMP, the hazard ratios for an exacerbation after 1-year follow-up in the low-risk and high-risk groups were 0.6 (95% CI, 0.5-0.7) and 1.9 (95% CI, 1.4-2.4), respectively, with similar results at 2 years. CONCLUSIONS: The proposed Asthma Exacerbation Clinical Score is simple to use and effective at identifying children at high and low risk for asthma exacerbations. The tool can easily be used in primary-care settings.
Authors: Helen K Reddel; D Robin Taylor; Eric D Bateman; Louis-Philippe Boulet; Homer A Boushey; William W Busse; Thomas B Casale; Pascal Chanez; Paul L Enright; Peter G Gibson; Johan C de Jongste; Huib A M Kerstjens; Stephen C Lazarus; Mark L Levy; Paul M O'Byrne; Martyn R Partridge; Ian D Pavord; Malcolm R Sears; Peter J Sterk; Stuart W Stoloff; Sean D Sullivan; Stanley J Szefler; Mike D Thomas; Sally E Wenzel Journal: Am J Respir Crit Care Med Date: 2009-07-01 Impact factor: 21.405
Authors: Wilson Quezada; Eun Soo Kwak; Joan Reibman; Linda Rogers; John Mastronarde; William G Teague; Christine Wei; Janet T Holbrook; Emily DiMango Journal: Ann Allergy Asthma Immunol Date: 2015-12-19 Impact factor: 6.347
Authors: Erick Forno; Joanne Sordillo; John Brehm; Wei Chen; Takis Benos; Qi Yan; Lydiana Avila; Manuel Soto-Quirós; Michelle M Cloutier; Angel Colón-Semidey; Maria Alvarez; Edna Acosta-Pérez; Scott T Weiss; Augusto A Litonjua; Glorisa Canino; Juan C Celedón Journal: J Allergy Clin Immunol Date: 2017-02-04 Impact factor: 10.793
Authors: Stephen J Teach; Peter J Gergen; Stanley J Szefler; Herman E Mitchell; Agustin Calatroni; Jeremy Wildfire; Gordon R Bloomberg; Carolyn M Kercsmar; Andrew H Liu; Melanie M Makhija; Elizabeth Matsui; Wayne Morgan; George O'Connor; William W Busse Journal: J Allergy Clin Immunol Date: 2015-03-18 Impact factor: 10.793
Authors: Margaret E Samuels-Kalow; Mohammad K Faridi; Janice A Espinola; Jean E Klig; Carlos A Camargo Journal: Acad Emerg Med Date: 2017-12-11 Impact factor: 3.451
Authors: Judie A Howrylak; Anne L Fuhlbrigge; Robert C Strunk; Robert S Zeiger; Scott T Weiss; Benjamin A Raby Journal: J Allergy Clin Immunol Date: 2014-05 Impact factor: 10.793